In brief: Rockeby, C3, Heartware

By Staff Writers
Friday, 04 March, 2005

Rockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.

Clinical Cell Culture (C3, ASX:CCE) has notched up the first commercial sale of spray-on-skin technology, ReCell, to its Japanese distributor and the announced the first use of ReCell in Japan. C3 Chief Executive Officer Troels Jordansen said the company had invoiced over AUD$400,000 in the first quarter of the calendar year in Japan.

HeartWare (ASX:HTW) has appointed corporate lawyer David McIntyre as chief financial officer and company secretary.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd